Walleye Trading LLC Uni Qure N.V. Transaction History

Walleye Trading LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $46,216 - $67,888	8,209 New	8,209 $55,000
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $306,979 - $378,717	16,416 New	16,416 $330,000
Q2 2022 Aug 08, 2022	BUY	$13.15 - $20.45 $149,028 - $231,759	11,333 New	11,333 $211,000
Q2 2021 Aug 16, 2021	SELL	$29.97 - $37.17 $62,487 - $77,499	-2,085 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$29.24 - $42.03 $60,965 - $87,632	2,085 New	2,085 $70,000
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $226,098 - $299,495	-6,284 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $92,282 - $138,731	2,048 Added 48.35%	6,284 $283,000
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $154,958 - $286,485	-3,873 Reduced 47.76%	4,236 $201,000
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $241,473 - $471,168	-6,135 Reduced 43.07%	8,109 $319,000
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $723,234 - $1.13 Million	13,708 Added 2557.46%	14,244 $1.11 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $14,681 - $36,667	536 New	536 $32,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.